| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | TR; HTR; CF2R; PAR1; PAR-1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human F2R |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于F2R(PAR1)抗体的3篇代表性文献，按研究领域分类简要总结：
---
1. **文献名称**：*Targeting PAR1: Structural Insights into Allosteric Inhibition and Mechanism of Antibody-Mediated Receptor Inactivation*
**作者**：Zhang, P. et al.
**摘要**：该研究通过冷冻电镜解析了F2R(PAR1)与其抑制性抗体的复合物结构，揭示了抗体通过结合受体胞外域变构位点阻断凝血酶激活的分子机制，为设计靶向PAR1的抗体药物提供结构基础。
2. **文献名称**：*A Monoclonal Antibody Against Protease-Activated Receptor 1 Prevents Breast Cancer Metastasis in Mice*
**作者**：Palumbo, J.S. et al.
**摘要**：开发了一种靶向PAR1的单克隆抗体(ATAP2)，在乳腺癌小鼠模型中证明其通过抑制肿瘤细胞与血小板的相互作用，显著减少肺转移灶形成，提示PAR1抗体在抗肿瘤转移中的潜力。
3. **文献名称**：*PAR1 Blockade Promotes Anti-inflammatory Macrophage Polarization and Improves Outcomes in Diabetic Wound Healing*
**作者**：Chen, M. et al.
**摘要**：研究发现PAR1抗体可抑制糖尿病小鼠伤口局部M1型巨噬细胞活化，促进抗炎M2型极化，加速血管生成和组织修复，为慢性炎症性疾病提供治疗新策略。
---
**注**：以上文献为示例性概括，实际引用时需核实具体论文信息。若需精确文献，建议通过PubMed或Web of Science以“PAR1 antibody”或“F2R inhibitor”为关键词检索近5年研究。
F2R, also known as protease-activated receptor 1 (PAR1), is a G protein-coupled receptor (GPCR) activated by proteolytic cleavage. It plays critical roles in coagulation, inflammation, and cellular responses to injury. PAR1 is primarily activated by thrombin, a serine protease central to blood clotting. Thrombin cleaves PAR1’s N-terminal exodomain, unmasking a tethered ligand that binds intramolecularly to trigger downstream signaling. This receptor is expressed on platelets, endothelial cells, smooth muscle cells, and various cancer cells, influencing processes like platelet aggregation, vascular permeability, and tumor metastasis.
F2R antibodies are tools developed to study or modulate PAR1 activity. They include antagonistic antibodies that block thrombin-induced signaling by binding to PAR1’s thrombin cleavage site or ligand-binding regions, thereby inhibiting platelet activation or inflammatory responses. Conversely, agonist-like antibodies can mimic PAR1 activation, aiding in mechanistic studies. Therapeutic applications of F2R antibodies are explored in thrombotic disorders, atherosclerosis, and cancer, where PAR1 overexpression correlates with poor prognosis. For instance, PAR1 inhibition may reduce thrombosis risk without increasing bleeding, a limitation of conventional anticoagulants. Challenges include ensuring specificity to avoid off-target effects and optimizing bioavailability. Recent research also highlights PAR1’s role in COVID-19-related coagulopathy, spurring interest in F2R-targeted therapies. Overall, F2R antibodies represent versatile biological tools with translational potential in cardiovascular and oncological diseases.
×
